Jefferies Raises Price Target#
Jefferies has increased its price target for Travere Therapeutics (NASDAQ:TVTX) from $42 to $50, while maintaining a Buy rating on the stock. Currently, shares are trading at $40.82, close to their 52-week high of $43.31. According to data, the stock is considered undervalued, with a fair value estimated at $50.24.
FSGS Approval and Market Potential#
The firm highlighted the low risk associated with launching Travere's drug, Filspari, following its approval for treating focal segmental glomerulosclerosis (FSGS). This approval is significant due to the high unmet medical need in this area. Filspari is also already marketed for immunoglobulin A nephropathy (IgAN), sharing similar prescriber contacts, which may facilitate its adoption.
Sales and Revenue Insights#
Jefferies estimates that first-quarter sales for IgAN will be around $106 million, slightly below the consensus estimate of $108 million. Travere has experienced a remarkable 110% revenue increase over the past year, and analysts expect the company to turn a profit this year after previous losses. However, it remains uncertain whether Travere will maintain its over 900 prescriptions from the fourth quarter, especially with Otsuka’s new drug, Voyxact, entering the market shortly after.
Future Prospects and Pipeline Developments#
The first-quarter prescription numbers will set a benchmark for future IgAN prescriptions, as Travere has indicated it will not separate revenue or prescription data for FSGS and IgAN in upcoming earnings reports. Jefferies also pointed out an important pipeline asset related to homocystinuria (HCU) that may gain attention as it progresses to phase III trials. The firm has increased its success probability estimates for both FSGS and HCU, reflecting a positive outlook for Travere's future.
In summary, the approval of Filspari marks a significant milestone for Travere Therapeutics, prompting analysts to adjust their ratings and price targets positively.